Skip to content

US · XLO · BIOTECHNOLOGY

Xilio Therapeutics, Inc. (XLO) intrinsic value and stock valuation

$7.56as of 2026-11-21 · Mkt cap 59.9M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Xilio Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values XLO with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from XLO’s statements →

Xilio Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Waltham, MA 02451 xiliotx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$43.8M
20192025
Net income
-$-35.04M
20192025
Free cash flow
-$-5.51M
20192025
Total equity
$35.3M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$43.8M$6.34M$0.00$0.00$0.00
Operating income-$-41.98M-$-60.58M-$-79.13M-$-89.15M-$-75.04M
Net income-$-35.04M-$-58.24M-$-76.4M-$-88.22M-$-75.8M
EPSd-$-419.19K-$-15.25M-$-38.98M-$-45.01M-$-189.5M
Operating cash flow-$-4.99M-$-18.38M-$-68.62M-$-75.72M-$-80.75M
Capital expenditure-$-520K-$-40K-$-490K-$-1.87M-$-1.1M
Free cash flow-$-5.51M-$-18.41M-$-69.11M-$-77.59M-$-81.85M
Total assets$154.7M$71.1M$60.9M$139.2M$221.6M
Total debt$6.95M$8.14M$12.5M$19.9M$20.7M
Net debt-$-130.58M-$-47.15M-$-32.2M-$-100.45M-$-177.32M
Total equity$35.3M$17.6M$36.8M$105.7M$185.4M
Cash and short-term investments$137.5M$55.3M$44.7M$120.4M$198.1M
Income statement
20252024202320222021
Revenue$43.8M$6.34M$0.00$0.00$0.00
Cost of revenue$1.54M$0.00$0.00$0.00$1.5M
Gross profit$42.2M$6.34M$0.00$0.00-$-1.5M
Research and development expenses$56M$41.2M$52.1M$59.2M$51.2M
Selling, general and administrative expenses$29.7M$24.8M$27M$30M$22.4M
Other expenses-$-1.54M$940K$0.00$0.00$0.00
Operating expenses$84.2M$66.9M$79.1M$89.2M$73.6M
Cost and expenses$85.8M$66.9M$79.1M$89.2M$75M
Interest income$3.4M$0.00$0.00$0.00$0.00
Interest expense$0.00$100K$0.00$0.00$600K
Depreciation and amortization$1.54M$1.64M$1.9M$1.85M$1.5M
Ebitda-$-33.49M-$-58M-$-74.5M-$-86.38M-$-73.7M
Operating income-$-41.98M-$-60.58M-$-79.13M-$-89.15M-$-75.04M
Total other income/expenses, net$6.95M$2.34M$2.73M$930K-$-760K
Income before tax-$-35.04M-$-58.24M-$-76.4M-$-88.22M-$-75.8M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-35.04M-$-58.24M-$-76.4M-$-88.22M-$-75.8M
Weighted average shares outstanding$83.6M$3.82M$1.96M$1.96M$400K
Weighted average diluted shares outstanding$83.6M$3.82M$1.96M$1.96M$400K
Balance sheet
20252024202320222021
Cash and short-term investments$137.5M$55.3M$44.7M$120.4M$198.1M
Net receivables$5M$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$145M$60.2M$48.1M$124.5M$202.5M
Property, plant and equipment, net$7.85M$9.06M$11.2M$12.8M$13.9M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$1.81M$1.78M$0.00$1.56M$1.55M
Total non-current assets$9.66M$10.8M$12.8M$14.7M$19.1M
Total assets$154.7M$71.1M$60.9M$139.2M$221.6M
Accounts payable$3.17M$2.57M$1.05M$3.12M$3.14M
Short-term debt$1.34M$1.19M$4.36M$7.58M$880K
Deferred revenue$40M$13.5M$0.00$0.00$0.00
Total current liabilities$56.3M$27.3M$16M$21.1M$12.8M
Long-term debt$5.61M$6.95M$8.14M$12.4M$19.9M
Deferred revenue, non-current$0.00$19.3M$0.00$0.00$0.00
Total non-current liabilities$63.1M$26.2M$8.14M$12.4M$23.4M
Capital lease obligations$6.95M$8.14M$9.19M$10.1M$10.2M
Total liabilities$119.4M$53.5M$24.1M$33.5M$36.2M
Common stock$36.9M$10K$0.00$0.00$0.00
Retained earnings-$-418.79M-$-383.75M-$-325.51M-$-249.11M-$-160.89M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$35.3M$17.6M$36.8M$105.7M$185.4M
Total investments$1.81M$1.78M$0.00$1.56M$1.55M
Total debt$6.95M$8.14M$12.5M$19.9M$20.7M
Net debt-$-130.58M-$-47.15M-$-32.2M-$-100.45M-$-177.32M
Cash flow statement
20252024202320222021
Net income-$-35.04M-$-58.24M-$-76.4M-$-88.22M-$-75.8M
Depreciation and amortization$1.54M$1.64M$1.9M$1.85M$1.5M
Stock-based compensation$6.94M$6.43M$7.38M$8.42M$4.96M
Change in working capital$25.1M$31.8M-$-1.66M$2M-$-11.8M
Accounts receivable-$-5M$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$150K$1.53M-$-2.06M$480K-$-2.82M
Net cash provided by operating activities-$-4.99M-$-18.38M-$-68.62M-$-75.72M-$-80.75M
Investments in property, plant and equipment-$-520K-$-40K-$-490K-$-1.87M-$-1.1M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-520K-$-40K-$-490K-$-1.87M-$-1.1M
Common stock issued$87.8M$6.83M$200K$20K$116.4M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$87.8M$29.2M-$-6.55M-$-70K$260.7M
Net change in cash$82.3M$10.8M-$-75.68M-$-77.67M$178.8M
Cash at end of period$139.3M$57.1M$44.7M$120.4M$199.6M
Operating cash flow-$-4.99M-$-18.38M-$-68.62M-$-75.72M-$-80.75M
Capital expenditure-$-520K-$-40K-$-490K-$-1.87M-$-1.1M
Free cash flow-$-5.51M-$-18.41M-$-69.11M-$-77.59M-$-81.85M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Xilio Therapeutics, Inc.

        Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.

        CEO
        Rene Russo
        Employees
        76
        Beta
        -0.12

        Explore

        Frequently asked questions

        What is the intrinsic value of Xilio Therapeutics, Inc. (XLO)?

        Xilio Therapeutics, Inc. (XLO) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is XLO undervalued?

        XLO trades at a price of $7.56 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.